Novel drugs in therapy of diabetes mellitus type 2

A tétel rövid nézete
dc.contributor.advisorSzentmiklósi, József András
dc.contributor.authorEtemadian Jahromi, Elnaz
dc.contributor.departmentDE--Fogorvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentVarga, Balázs
dc.date.accessioned2017-05-31T08:03:57Z
dc.date.available2017-05-31T08:03:57Z
dc.date.created2015-12-10
dc.description.abstracttype 2 diabetes mellitus is an ever increasing complex endocrine and metabolic disorder while its management has still remains as a complex and challenging issue and the need for novel approaches to treat hyperglycemia simply cannot be ignored. SGLT 2 inhibitors are also reliable new class of antidiabetic drugs such as Dapagliflozin and Canagliflozin are currently approved in the US, Europe and Japan. They cause both weight loss and glycemic control effectively with a low risk of hypoglycemia.However, it is still not certain if SGLT2 inhibitors can improve the clinical effect of diabetes, like micro- or macrovascular late complications.hu_HU
dc.description.correctorgj
dc.description.coursefogorvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/241169
dc.language.isoenhu_HU
dc.subjectdiabetes mellitus type 2hu_HU
dc.subjectNovel drugshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleNovel drugs in therapy of diabetes mellitus type 2hu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Dentistry)